公开(公告)号：US20160280649A1

公开(公告)日：2016-09-29

申请号：US15034915

申请日：2014-01-16

Applicant: Bristol-Myers Squibb Company

Inventor： Ryan M. MOSLIN ,  David S. WEINSTEIN ,  Stephen T. WROBLESKI ,  Yanlei ZHANG ,  John S. TOKARSKI ,  Michael E. MERTZMAN ,  Chunjian LIU

IPC: C07D213/82 ,  C07D417/12 ,  C07D413/12 ,  C07B59/00 ,  C07D405/12 ,  C07D401/12

CPC classification number: A61K31/455 ,  A61K31/44 ,  A61K31/444 ,  A61K31/506 ,  C07B59/002 ,  C07B2200/05 ,  C07D213/56 ,  C07D213/82 ,  C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12

Abstract: Compounds having the following formula (I): or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα by acting on Tyk-2 to cause signal transduction inhibition.

Abstract translation: 具有下式（I）的化合物或其立体异构体或其药学上可接受的盐，其中R 1，R 2，R 3，R 4和R 5如本文所定义，可用于调节IL-12，IL-23和 /或IFNa作用于Tyk-2以引起信号转导抑制。

公开(公告)号：US20230089255A1

公开(公告)日：2023-03-23

申请号：US17786442

申请日：2020-12-18

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Susan WEE ,  Joseph L. BENC ,  Xinyu WANG ,  Upender VELAPARTHI ,  Louis S. CHUPAK ,  Chatan P. DARNE ,  Min DING ,  Robert G. GENTLES ,  Yazhong HUANG ,  Scott W. MARTIN ,  Ivar M. MCDONALD ,  Richard E. OLSON ,  Xiaofan ZHENG ,  John S. TOKARSKI ,  Bireshwar DASGUPTA ,  Manjunatha Narayana Rao KAMBLE ,  Raju MANNOORI ,  Haslbur RAHAMAN ,  Prasada Rao JALAGAM ,  Saumya ROY ,  Gopikishan TONUKUNURU ,  Sivasudar VELAIAH ,  Jayakumar Sankara WARRIER ,  Kotha Rathnakar REDDY ,  Thiruvenkadam RAJA ,  Denise GRUNENFELDER ,  Michael WICHROSKI

IPC: A61K31/519 ,  A61K31/496 ,  A61K39/395 ,  A61P35/00

Abstract: Provided are inhibitors of diacylglycerol kinases (DGK) and methods for treating diseases that would benefit from the stimulation of the immune system, such as cancer and infections diseases, comprising administering a DGK inhibitor in combination with an antagonist of the PD 1/PD-L 1 axis and/or an antagonist of CTLA4.